Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia.
Suzuki
Haruyuki
H
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Sugimura
Yoshihisa
Y
Iwama
Shintaro
S
Suzuki
Hiromi
H
Nobuaki
Ozaki
O
Nagasaki
Hiroshi
H
Arima
Hiroshi
H
Sawada
Makoto
M
Oiso
Yutaka
Y
D000704:Analysis of Variance; D000818:Animals; D002478:Cells, Cultured; D016207:Cytokines / Q000378:metabolism*; D003711:Demyelinating Diseases / Q000517:prevention & control*; D004195:Disease Models, Animal; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D007010:Hyponatremia / Q000188:drug therapy* / Q000473:pathology; D007150:Immunohistochemistry; D008297:Male; D020782:Matrix Metalloproteinases / Q000187:drug effects / Q000378:metabolism; D017628:Microglia / Q000187:drug effects*; D008911:Minocycline / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction
D016207:Cytokines; D012333:RNA, Messenger; D020782:Matrix Metalloproteinases; D008911:Minocycline